NCT00687219View on ClinicalTrials.gov

Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)

PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Hepatitis C, ChronicLiver Cirrhosis
Interventions
BIOLOGICAL

Peginterferon alfa-2b

Administered at 1.0 µg/kg/week SC for 48 weeks

DRUG

Ribavirin

Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening \>=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening \>=12g/dL and \<14g/dL; treatment duration is 48 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00687219 - Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) | Biotech Hunter | Biotech Hunter